Novo Nordisk successfully completes phase 2 trial with CagriSema in people with type 2 diabetes

cafead

Administrator
Staff member
  • cafead   Aug 22, 2022 at 10:12: AM
via Novo Nordisk today announced headline results from a phase 2 clinical trial with CagriSema, a once-weekly subcutaneous combination of semaglutide and a novel amylin analogue, cagrilintide.

article source